This Week Health
SOAR 2024 Bluebird Leaders This Week HealthAlex's Lemonade Stand This Week Health
SUBSCRIBE NOW to receive top 7 stories daily to your inbox
<--  All Stories

Parkinson's Drug Reduces Disease Markers in Breakthrough Trial

March 13, 2024
ScienceAlert
Contributed by: Reid Stephan
Summary
A novel therapy developed by Vaxxinity, codenamed UB-312, is showing promise in early clinical trials for treating Parkinson’s disease by targeting and reducing toxic clumps of alpha-synuclein protein in cerebrospinal fluid, a key factor believed to drive the disease's progression. This groundbreaking approach marks a significant advancement in the potential treatment and prevention of Parkinson's, offering hope for disease-modifying treatment. Early trial results suggest that UB-312 can lower levels of harmful protein aggregates, which may lead to improved motor function in patients. While the therapy is still under investigation and requires further testing to confirm its safety and efficacy, it represents a hopeful development for the nearly one million Americans currently diagnosed with Parkinson’s and those who will be diagnosed in the future.
Transform Healthcare - One Connection at a Time

© Copyright 2024 Health Lyrics All rights reserved